Physician profile
Lia Head
NPI 1043674161
$4,205.40
in general payments reported to CMS, 2019-2025
47 companies · $3,156 in 2025
The $3,156 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.83 · 2023: $15.18 · 2024: $1,019 · 2025: $3,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,016.98 |
| Education | $173.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $699.75 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $247.92 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $241.70 | 2025 | Provenge |
| Pfizer INC. | $205.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $190.03 | 2023-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $160.76 | 2024-2025 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $135.33 | 2024-2025 | Erleada, Balversa, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $122.43 | 2024-2025 | Ninlaro, Iclusig, Fruzaqla |
| Glaxosmithkline, LLC. | $114.28 | 2025 | Zejula, Jemperli |
| Koya Medical, INC. | $108.36 | 2025 | Koya Medical, Dayspring |
| Incyte Corporation | $105.92 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Astellas Pharma US INC | $95.14 | 2024-2025 | Vyloy, Xtandi, Cresemba |
| Exelixis INC. | $90.39 | 2024-2025 | Cabometyx |
| Celgene Corporation | $90.35 | 2022-2025 | Reblozyl, Breyanzi |
| Array Biopharma INC | $89.03 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lia Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.